Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range

Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range

Antagonism of the dopamine D3 receptor has been hypothesized to be beneficial for schizophrenia cognitive deficits, negative symptoms and extrapyramidal symptoms. However, recent animal and human studies have shown that most antipsychotics do not occupy D3 receptors in vivo, despite their considerab...

Full description

Bibliographic Details
Main Authors:	Satoko Baba, Takeshi Enomoto, Tomoko Horisawa, Takashi Hashimoto, Michiko Ono
Format:	Article
Language:	English
Published:	Elsevier 2015-03-01
Series:	Journal of Pharmacological Sciences
Subjects:	Dopamine D3 receptor D2 receptor Antipsychotic Occupancy
Online Access:	http://www.sciencedirect.com/science/article/pii/S1347861315000109

Similar Items

Antipsychotic Induced Dopamine Receptor Supersensitivity and It’s Clinical Implications
by: Riko Lazuardi, et al.
Published: (2022-05-01)

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
by: Mitsukuni Murasaki, et al.
Published: (2021-09-01)

Carbazole and tetrahydro-carboline derivatives as dopamine D3 receptor antagonists with the multiple antipsychotic-like properties
by: Zhongtang Li, et al.
Published: (2023-11-01)

Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
by: Jean Claude Martel, et al.
Published: (2020-07-01)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020-11-01)

Taq1A polymorphism in patients with bipolar disorder: A candidate gene study based on the dopamine hypothesis
by: Kiyomitsu Ota, et al.
Published: (2023-06-01)

Total Barley Maiya Alkaloids Prevent Increased Prolactin Levels Caused by Antipsychotic Drugs and Reduce Dopamine Receptor D2 via Epigenetic Mechanisms
by: Yu-Ling Cao, et al.
Published: (2022-07-01)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01)

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
by: U. Shivraj Sohur, et al.
Published: (2018-10-01)

Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors
by: Jaromir Myslivecek
Published: (2022-04-01)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
by: Stuart H. Isaacson, et al.
Published: (2023-01-01)

Dopamine dilemma: case report of treating psychosis in patient with retinitis pigmentosa
by: Haitham Salem, et al.
Published: (2019-01-01)

Auxiliary role of D5 dopamine receptor as a marker in paranoid schizophrenia patients
by: Mahkameh Soleiman Meygooni, et al.
Published: (2019-04-01)

Deciphering the actions of antiparkinsonian and antipsychotic drugs on cAMP/DARPP-32 signaling
by: Gilberto eFisone, et al.
Published: (2011-07-01)

Successful treatment of dopamine dysregulation syndrome with dopamine D<sub>2</sub> partial agonist antipsychotic drug
by: Mizushima Jin, et al.
Published: (2012-07-01)

Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection
by: Federica Bono, et al.
Published: (2020-07-01)

Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients
by: Helle G. Andersen, et al.
Published: (2020-05-01)

Expression of a novel D4 dopamine receptor in the lamprey brain. Evolutionary considerations about dopamine receptors.
by: Juan ePérez-Fernández, et al.
Published: (2016-01-01)

Development and Characterization of Novel Selective, Non-Basic Dopamine D<sub>2</sub> Receptor Antagonists for the Treatment of Schizophrenia
by: Piotr Stępnicki, et al.
Published: (2023-05-01)

Dopamine D3 receptors inhibit hippocampal gamma oscillations by disturbing CA3 pyramidal cell firing synchrony
by: Clément E. Lemercier, et al.
Published: (2016-01-01)

Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia
by: Zijin Feng, et al.
Published: (2024-01-01)

Loss of Function in Dopamine D3 Receptor Attenuates Left Ventricular Cardiac Fibroblast Migration and Proliferation in vitro
by: Andrew Kisling, et al.
Published: (2021-10-01)

Microinjection of a dopamine-D1 receptor agonist into the ventral tegmental area reverses the blocked expression of morphine conditioned place preference by N-methyl-D-aspartate receptor antagonist
by: Seyed Mostafa Ahmadian, et al.
Published: (2020-01-01)

Evaluation of Substituted <i>N</i>-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands
by: Boeun Lee, et al.
Published: (2021-05-01)

Spatial Working Memory in Male Rats: Pre-Experience and Task Dependent Roles of Dopamine D1- and D2-Like Receptors
by: Mekite Bezu, et al.
Published: (2017-10-01)

Neuroleptic malignant syndrome: the diagnostic dilemma
by: Ivana Stasevic Karlicic, et al.
Published: (2016-07-01)

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
by: Vanja Mandic-Maravic, et al.
Published: (2022-02-01)

Immunolocalization of kappa opioid receptors in the axon initial segment of a group of embryonic mesencephalic dopamine neurons
by: Angélica Pilar Escobar, et al.
Published: (2022-06-01)

Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor
by: Pramisha Adhikari, et al.
Published: (2021-04-01)

Effects of Dopamine on the Immature Neurons of the Adult Rat Piriform Cortex
by: Simona Coviello, et al.
Published: (2020-10-01)

Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia
by: Francesco Napolitano, et al.
Published: (2010-06-01)

Dopamine D1 Receptor in Cancer
by: Paweł Sobczuk, et al.
Published: (2020-11-01)

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias
by: Rosario Sánchez-Pernaute, et al.
Published: (2007-08-01)

The role of intracerebral dopamine D1 and D2 receptors in sleep‐wake cycles and general anesthesia
by: Jie Zhang, et al.
Published: (2022-03-01)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
by: Kathryn Lanza, et al.
Published: (2021-03-01)

Antipsychotic-induced bone loss: the role of dopamine, serotonin and adrenergic receptor signalling
by: D. Kavindi Weerasinghe, et al.
Published: (2023-05-01)

Synthesis and pharmacological evaluation of several N-(2-nitrophenyl) piperazine derivatives
by: Andrić Deana, et al.
Published: (2007-01-01)

Diversity and bias through receptor-receptor interactions in GPCR heteroreceptor complexes. Focus on examples from dopamine D2 receptor heteromerization
by: Kjell eFuxe, et al.
Published: (2014-05-01)

To Do or Not to Do: Dopamine, Affordability and the Economics of Opportunity
by: Jeff A. Beeler, et al.
Published: (2018-02-01)

DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs
by: Antonio Del Casale, et al.
Published: (2023-07-01)